GALNT14 genotype-guided, sorafenib in combination with transarterial chemoembolization in hepatocellular carcinoma: An interim report of a prospective randomized controlled trial.

Chau-Ting Yeh,Wei-Chen Lee,Shi-Ming Lin,Chih-Lang Lin,Chao-Wei Hsu,Ting-Jung Wu,Ming Chin Yu,Chien-Fu Hung,Jeng-Hwei Tseng,Chen Chun Lin,Wei-Ting Chen,Wei Teng,Yi-Cheng Chen,Ming-Ling Chang

GALNT14 genotype-guided, sorafenib in combination with transarterial chemoembolization in hepatocellular carcinoma: An interim report of a prospective randomized controlled trial.

2017

Chau-Ting Yeh
Wei-Chen Lee
Shi-Ming Lin
Chih-Lang Lin
Chao-Wei Hsu
Ting-Jung Wu
Ming Chin Yu
Chien-Fu Hung
Jeng-Hwei Tseng
Chen Chun Lin
Wei-Ting Chen
Wei Teng
Yi-Cheng Chen
Ming-Ling Chang

e15657Background: Sorafenib is the only approved targeted agent for treatment of unresectable hepatocellular carcinoma (HCC). Transarterial chemoembolization (TACE) is the mainstay of treatment for...

Keywords:

Physical therapy
Randomized controlled trial
Hepatocellular carcinoma
Interim
Genotype
Sorafenib
Cancer research
Medicine
Oncology
Internal medicine
interim report
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations